Gujarat Themis Biosyn Limited — Investor Meet, 14-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

GTBL Q1 FY27 saw 22.1% YoY revenue growth to INR 43.8 Cr, with PAT also up 22.1% to INR 11.1 Cr. EBITDA soared 49.4% to INR 20.8 Cr, driving a 47.5% margin. Sales volume led this robust growth.

Management is transforming GTBL into an integrated fermentation-led CDMO. Key acquisitions like MicroBiopharm Japan enhance advanced tech, R&D, and add therapy areas (immunosuppressants, oncology). The Sanofi brand portfolio expands global commercial reach (55 countries) for anti-TB/infective brands, enabling forward integration. These strategic moves aim for higher-value opportunities and diversified growth.

Fermentation capacity has doubled, with the API block now ready. Full operational output from expanded capacity is expected by end of this month, contributing to H2 FY27 results. Management expects significant asset turns from these investments and high-teen growth, aiming for current margin levels post integration.

Q&A revealed that prior flat revenue was due to sold-out capacity and capex delays, now resolved. Acquisitions are cash flow positive, with synergies anticipated within the first year. Promoter pledge is expected to reduce significantly in 12-15 months. Management maintains a confident outlook, emphasizing disciplined execution and long-term value creation.